Hematology Service, Hospital Universitario, UANL, Paris 3029 Col. Cumbres, 64610, Monterrey, N.L., Mexico.
Arch Immunol Ther Exp (Warsz). 2012 Apr;60(2):99-106. doi: 10.1007/s00005-012-0164-3. Epub 2012 Feb 4.
Antibodies have been the cornerstone of treatment of acquired aplastic anemia for more than 25 years. Treatment with antithymocyte globulin (ATG) is considered pivotal and the addition of cyclosporine improves the overall response rate. This antibody is heterogeneous and horse ATG is apparently more effective than rabbit ATG. Several issues remain unsolved in relation to the combination of ATG and cyclosporine: cost, toxicity and late clonal disorders. In recent years, alternative immunosuppressive therapy has been proposed and new antibodies have emerged: porcine ATG, alemtuzumab, daclizumab, and rituximab. Experience with these antibodies is limited to a few studies with alemtuzumab being the most promising, but the results are interesting and provocative. More studies are needed to find the perfect antibody.
抗体已经成为治疗获得性再生障碍性贫血 25 年以上的基石。抗胸腺细胞球蛋白（ATG）的治疗被认为是关键的，环孢素的加入提高了总体反应率。这种抗体是异质的，马 ATG 显然比兔 ATG 更有效。在 ATG 和环孢素联合使用方面，仍有几个问题尚未解决：成本、毒性和晚期克隆疾病。近年来，提出了替代免疫抑制疗法，出现了新的抗体：猪 ATG、阿仑单抗、达利珠单抗和利妥昔单抗。这些抗体的经验仅限于少数阿仑单抗的研究，最有前途，但结果是有趣和有启发性的。需要更多的研究来找到完美的抗体。
